2021 Honorees: NFL Alumni Health, the Klein Family), Feng Zhang, PhD and the Global Immunization Action Network Team (GIANT) and Joseph P. Vacanti, MD.
E-Mail
IMAGE: Research team from Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam. view more
Credit: AlphaMed Press
Durham, NC Type 2 diabetes patients who are not overweight and who have had the disorder for less than a decade can benefit from stromal stem cells transplanted from their own bone marrow, according to a study published today in
STEM CELLS Translational Medicine.
In a randomized clinical trial at Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam, researchers investigated the safety and potential therapeutic value of administering bone marrow stromal stem cells to patients with Type 2 diabetes. In each case, the cells were autologous, or taken from the patients own bodies.
by Barry Teater, NCBiotech Writer May 13, 2021 .
RESEARCH TRIANGLE PARK The North Carolina Biotechnology Center awarded 48 grants and loans totaling nearly $1.8 million to universities, bioscience companies and other entities in the third quarter of its fiscal year.
The awards, made in January, February and March, support life sciences research, technology commercialization and entrepreneurship throughout North Carolina. The funding also helps universities and companies attract follow-on funding from other sources.
Company loans
Three bioscience companies received Small Business Research Loans totaling $550,000 to advance their research, product development and commercial viability.
Alacrity Medical Innovations of Chapel Hill received $100,000 to complete prototype development and prepare for an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration for a disposable, drug-device combination product that treats mild to moderate bleeding in patients
A study released in STEM CELLS Translational Medicine offers hope for those suffering from a chronic, difficult to treat condition called non-tuberculous mycobacteria (NTM) lung infection.
Share:
MIAMI, April 27, 2021 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ:LGVN) ( Longeveron or Company ), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announces it has been selected to present at the 2021 World Stem Cell Summit taking place virtually on June 14-18, in combination with the Wake Forest Institute for Regenerative Medicine (WFIRM) and Regenerative Medicine Foundation (RMF).
Dr. Joshua Hare, Co-Founder and Chief Science Officer, is scheduled to present in a session titled The Longevity Agenda: Canceling the Pathologies of Aging. Longeveron will also provide a pre-recorded 4-5 minute presentation as part of the Investment & Commercialization Forum Track of the Summit.